Secondary
Verastem, Inc.
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways.
Symbol
VSTM
Last Closing Price
$3.65
Effective Date
December 15, 2017
Underwriters
BTIG
To view the prospectus for Verastem, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277